Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Phase III awaiting (ie completed phase II, not yet in III) -- Ignore unavailable to you. Want to Upgrade?

To: QuietWon who wrote (12)	1/31/1999 11:40:00 PM
From: bob	Read Replies (1) \| Respond to of 32

Thanks QuietWon for your information. Phase III APC results with Prevatac due to be published within two weeks. Phase II/III results on prostate cancer due to be published by March or April. APC results expected to be excellent and on fast track for FDA approval. If results are good, stock will trade over $30 IMO. If results for prostate are good, stock will go to $100. Potential $200-300 stock in a year or two. If FDA grants approval, Prevatac will be on the market by 4th quarter of 99.